Suppliers and packagers for generic pharmaceutical drug: AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Azurity	WIDAPLIK	amlodipine besylate; indapamide; telmisartan	TABLET;ORAL	219423	NDA	Azurity Pharmaceuticals, Inc.	24338-001-30	30 TABLET in 1 BOTTLE (24338-001-30)	2025-10-20
Azurity	WIDAPLIK	amlodipine besylate; indapamide; telmisartan	TABLET;ORAL	219423	NDA	Azurity Pharmaceuticals, Inc.	24338-002-30	30 TABLET in 1 BOTTLE (24338-002-30)	2025-10-20
Azurity	WIDAPLIK	amlodipine besylate; indapamide; telmisartan	TABLET;ORAL	219423	NDA	Azurity Pharmaceuticals, Inc.	24338-003-30	30 TABLET in 1 BOTTLE (24338-003-30)	2025-10-20

Pharmaceutical Supply Chain Analysis: Amlodipine Besylate, Indapamide, and Telmisartan

Last updated: February 19, 2026

This report details the global supply landscape for active pharmaceutical ingredients (APIs) and key intermediates essential for the manufacture of amlodipine besylate, indapamide, and telmisartan. It identifies leading suppliers, production capacities, patent expiries, and regulatory considerations impacting the availability and pricing of these critical cardiovascular medications.

What is the current global supply status for amlodipine besylate API?

The global supply of amlodipine besylate API is characterized by a significant concentration of manufacturers, primarily in Asia, with India and China dominating production. The market is mature, with numerous generic manufacturers vying for market share.

Key Amlodipine Besylate API Suppliers:

• Sun Pharmaceutical Industries Ltd. (India): A major producer of amlodipine besylate API, with integrated manufacturing facilities. [1]
• Dr. Reddy's Laboratories (India): Offers amlodipine besylate API as part of its extensive generic portfolio.
• Lupin Ltd. (India): A significant player in the generics API market, including amlodipine besylate.
• Teva Pharmaceutical Industries Ltd. (Israel): A global leader in generics, with amlodipine besylate API production capabilities.
• Hetero Labs Ltd. (India): Known for its large-scale API manufacturing, including amlodipine besylate.
• Aarti Industries Ltd. (India): A key manufacturer of specialty chemicals and pharmaceuticals, including amlodipine besylate intermediates and API. [2]

Production Capacity & Trends: Global production capacity for amlodipine besylate API is estimated to be substantial, exceeding current market demand, which supports competitive pricing. However, disruptions in raw material sourcing or significant shifts in regulatory compliance can impact availability. Manufacturers are continuously investing in process optimization to reduce costs and improve yield.

Patent Landscape: The primary patents for amlodipine besylate have long since expired. This has facilitated the widespread generic entry and established a highly competitive API market. The focus for intellectual property now lies in novel formulations, delivery systems, or combination therapies.

What are the primary manufacturing challenges and regulatory considerations for amlodipine besylate API?

Manufacturing amlodipine besylate API involves complex multi-step synthesis requiring stringent quality control. Key challenges include managing impurity profiles, ensuring consistent polymorphic forms, and adhering to Good Manufacturing Practices (GMP).

Regulatory Oversight: Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) conduct rigorous inspections of API manufacturing facilities. Compliance with ICH guidelines, particularly ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), is mandatory.

• FDA Inspections: Facilities supplying the U.S. market must pass FDA inspections, which scrutinize quality management systems, process validation, and analytical testing. [3]
• EMA Requirements: European Union member states require Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) for APIs used in medicinal products within the EU. [4]
• Impurity Control: Strict limits are placed on known and unknown impurities, including genotoxic impurities. Manufacturers must demonstrate robust impurity profiling and control strategies.
• Environmental Regulations: Increasing scrutiny on environmental impact necessitates sustainable manufacturing processes and waste management.

What is the current global supply status for indapamide API?

The indapamide API market is also largely supplied by manufacturers in India and China, reflecting the broader trend in generic API production. The market is characterized by a stable supply chain for established manufacturers.

Key Indapamide API Suppliers:

• Divi's Laboratories Ltd. (India): A significant producer of various APIs, including indapamide, with a strong regulatory track record. [5]
• Granules India Ltd. (India): Manufactures indapamide API for global markets.
• Taj Pharmaceuticals Ltd. (India): Offers indapamide API as part of its generic pharmaceutical offerings.
• Amneal Pharmaceuticals (USA): While primarily a finished dosage form manufacturer, Amneal may source or produce indapamide API.
• Various Chinese Manufacturers: Several Chinese API producers are active in the indapamide market, often competing on price.

Production Capacity & Trends: Indapamide API production capacity is sufficient to meet global demand. The market is sensitive to raw material costs, particularly for key intermediates. Continuous process improvement is a focus for manufacturers to maintain competitive pricing.

Patent Landscape: Similar to amlodipine besylate, the fundamental patents covering indapamide have expired, allowing for widespread generic production. Innovation in this space typically relates to particle size engineering or alternative salt forms to improve bioavailability or stability.

What are the primary manufacturing challenges and regulatory considerations for indapamide API?

The synthesis of indapamide involves specific chemical reactions that require precise control over reaction conditions to ensure purity and yield. Challenges include managing chiral impurities if applicable and ensuring the correct crystalline form.

Regulatory Oversight: Manufacturers supplying indapamide API to regulated markets must comply with stringent GMP standards.

• DMF Filings: U.S. manufacturers typically file Drug Master Files (DMFs) with the FDA detailing the manufacturing process, controls, and facility. [3]
• GMP Compliance: Audits by regulatory agencies focus on manufacturing processes, quality control, and documentation to ensure product safety and efficacy.
• Impurity Profiling: Manufacturers must identify and quantify all process-related impurities and degradation products.
• Supply Chain Traceability: Robust systems for tracking raw materials and finished APIs are essential for regulatory compliance and market access.

What is the current global supply status for telmisartan API?

Telmisartan, a widely prescribed angiotensin II receptor blocker (ARB), has a global API market dominated by manufacturers in India and China. The demand for telmisartan API is driven by its efficacy in treating hypertension and its use in combination therapies.

Key Telmisartan API Suppliers:

• Sun Pharmaceutical Industries Ltd. (India): A significant supplier of telmisartan API.
• Dr. Reddy's Laboratories (India): Offers telmisartan API as part of its ARB portfolio.
• Divi's Laboratories Ltd. (India): A major player in API manufacturing, including telmisartan. [5]
• Cadila Healthcare Ltd. (India): A prominent Indian pharmaceutical company with API manufacturing capabilities for telmisartan.
• Mylan N.V. (now Viatris, USA/India): Through its various entities, Mylan has been a supplier of telmisartan API.
• Various Chinese Manufacturers: Chinese companies contribute significantly to the global supply, often with competitive pricing.

Production Capacity & Trends: Global production capacity for telmisartan API is well-established and generally aligns with market demand. However, fluctuations in raw material availability, particularly for key starting materials like substituted benzimidazoles, can influence supply stability. Cost-effectiveness is a primary driver, leading to ongoing process optimization by manufacturers.

Patent Landscape: The original composition of matter patents for telmisartan have expired in major markets. Generic competition is robust. Research and development efforts are directed towards new polymorphs, improved synthetic routes, and combination products with other antihypertensive agents.

What are the primary manufacturing challenges and regulatory considerations for telmisartan API?

The synthesis of telmisartan involves complex organic chemistry, including the formation of the benzimidazole core and subsequent functionalization. Key challenges include controlling stereochemistry if specific enantiomers are targeted, managing by-products, and ensuring batch-to-batch consistency.

Regulatory Oversight: Suppliers of telmisartan API must meet rigorous international regulatory standards.

• ICH Q7 Compliance: Adherence to GMP for APIs is non-negotiable. [3]
• ANDA/MAA Support: API manufacturers must provide comprehensive documentation to support Abbreviated New Drug Applications (ANDAs) in the U.S. and Marketing Authorisation Applications (MAAs) in Europe.
• Impurity Control: Stringent limits on related substances, residual solvents, and potential genotoxic impurities are enforced by regulatory agencies.
• Data Integrity: Ensuring the accuracy, completeness, and reliability of all manufacturing and quality control data is paramount during regulatory inspections.
• Supply Chain Security: Manufacturers are increasingly focused on securing their supply chains against counterfeiting and ensuring the integrity of the entire production process.

Comparative Analysis of Supply Chains

Feature	Amlodipine Besylate	Indapamide	Telmisartan
Primary Producers	India, China	India, China	India, China
Market Maturity	Mature, highly competitive generic market	Mature, stable generic market	Mature, competitive generic market
Key Suppliers	Sun Pharma, Dr. Reddy's, Lupin, Teva, Hetero, Aarti	Divi's Labs, Granules India, Taj Pharma, Amneal	Sun Pharma, Dr. Reddy's, Divi's Labs, Cadila, Mylan
Patent Status	Expired	Expired	Expired
Regulatory Focus	GMP, Impurity Profile, Polymorphism	GMP, Impurity Profile, Raw Material Sourcing	GMP, Impurity Profile, By-product Control
Cost Drivers	Raw Material Costs, Manufacturing Efficiency	Raw Material Costs, Energy Costs	Raw Material Costs, Process Optimization
Innovation Focus	Formulations, Combinations	Polymorphism, Bioavailability	Polymorphism, Improved Synthesis, Combinations

Key Takeaways

The global supply of amlodipine besylate, indapamide, and telmisartan APIs is robust and primarily concentrated in India and China, supported by numerous manufacturers with established GMP compliance. Patent expiries have led to highly competitive generic API markets for all three drugs, emphasizing cost efficiency and consistent quality as primary differentiators. Regulatory compliance, particularly adherence to GMP and stringent impurity control, is critical for market access and supplier qualification. While supply chains are generally stable, manufacturers must remain vigilant regarding raw material sourcing, process optimization, and evolving regulatory landscapes to maintain competitive advantage and ensure uninterrupted product availability.

FAQs

1. What is the typical lead time for ordering these APIs from major suppliers? Lead times generally range from 8 to 16 weeks for standard orders, depending on supplier inventory, production schedules, and shipping logistics. Expedited orders may be possible at a premium.

2. How does the regulatory status of a supplier's manufacturing site (e.g., FDA inspection history) impact sourcing decisions? A positive regulatory history, including successful FDA and EMA inspections and the absence of significant warning letters, is a critical factor. It indicates compliance with quality standards and reduces the risk of supply disruptions due to regulatory actions.

3. Are there significant differences in API quality or impurity profiles between different manufacturers? While all APIs must meet pharmacopeial standards, subtle differences in manufacturing processes can lead to variations in impurity profiles and physical characteristics (e.g., particle size, polymorphism). Due diligence, including review of analytical data and potentially site audits, is essential.

4. What are the primary geopolitical risks affecting the supply chain for these APIs? Geopolitical risks include trade disputes, export/import restrictions, political instability in key manufacturing regions, and disruptions to global shipping caused by international conflicts or health crises.

5. How does the cost of key starting materials influence the final API price? The cost of key starting materials is a significant determinant of API pricing. Fluctuations in commodity prices or availability of these intermediates directly impact the cost of production and, consequently, the market price of amlodipine besylate, indapamide, and telmisartan APIs.

Citations

[1] Sun Pharmaceutical Industries Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Supplier Website - specific URL omitted for generality]

[2] Aarti Industries Ltd. (n.d.). Pharmaceuticals. Retrieved from [Supplier Website - specific URL omitted for generality]

[3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files/

[4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from https://www.edqm.eu/en/certificates-suitability-cep

[5] Divi's Laboratories Ltd. (n.d.). Products. Retrieved from [Supplier Website - specific URL omitted for generality]